Spermine and Citrate as Metabolic Biomarkers for Assessing Prostate Cancer Aggressiveness

PLoS ONE

Volumn 8, Issue 4, 2013, Pages

  Giskeødegård, Guro F ^a,b   Bertilsson, Helena ^a,b   Selnæs, Kirsten M ^a,b   Wright, Alan J ^c   Bathen, Tone F ^a,b   Viset, Trond ^b   Halgunset, Jostein ^a,b   Angelsen, Anders ^a,b   Gribbestad, Ingrid S ^a,b   Tessem, May Britt ^a,b  

^a NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^b TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINE; CITRIC ACID; CREATINE; POLYAMINE; SPERMINE; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER GROWTH; CANCER PROGNOSIS; CANCER STAGING; CONTROLLED STUDY; CORRELATIONAL STUDY; DIAGNOSTIC TEST ACCURACY STUDY; GLEASON SCORE; HIGH RESOLUTION MAGIC ANGLE SPINNING MAGNETIC RESONANCE SPECTROSCOPY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; METABOLITE; MULTIVARIATE ANALYSIS; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PREDICTIVE VALUE; PROSTATE CANCER; PROSTATECTOMY; QUANTITATIVE STUDY; SENSITIVITY AND SPECIFICITY; TISSUE DISTRIBUTION; DISEASE COURSE; ELECTRON SPIN RESONANCE; METABOLISM; METABOLOMICS; MIDDLE AGED; PROSTATIC NEOPLASMS; TUMOR VOLUME;

AGED; CITRIC ACID; DISEASE PROGRESSION; ELECTRON SPIN RESONANCE SPECTROSCOPY; HUMANS; MALE; METABOLOMICS; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; PROSTATIC NEOPLASMS; SPERMINE; TUMOR BURDEN; TUMOR MARKERS, BIOLOGICAL;

EID: 84876574028     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0062375     Document Type: Article

References (38)

1. Epstein JI, Allsbrook WC Jr, Amin MB, Egevad LL, (2005) The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma. American Journal of Surgical Pathology 29: 1228-1242.
2. Hanahan D, Weinberg Robert A, (2011) Hallmarks of Cancer: The Next Generation. Cell 144: 646-674.
3. Bathen TF, Sitter B, Sjøbakk TE, Tessem M-B, Gribbestad IS, (2010) Magnetic Resonance Metabolomics of Intact Tissue: A Biotechnological Tool in Cancer Diagnostics and Treatment Evaluation. Cancer Research 70: 6692-6696.
4. García-Martín ML, Adrados M, Ortega MP, Fernández González I, López-Larrubia P, et al. (2011) Quantitative 1H MR spectroscopic imaging of the prostate gland using LCModel and a dedicated basis-set: Correlation with histologic findings. Magnetic Resonance in Medicine 65: 329-339.
5. Fütterer JJ, Scheenen TWJ, Heijmink SWTPJ, Huisman HJ, Hulsbergen-Van de Kaa CA, et al. (2007) Standardized Threshold Approach Using Three-Dimensional Proton Magnetic Resonance Spectroscopic Imaging in Prostate Cancer Localization of the Entire Prostate. Investigative radiology 42: 116-122.
6. Kurhanewicz J, Vigneron D, Carroll P, Coakley F, (2008) Multiparametric magnetic resonance imaging in prostate cancer: present and future. Current opinion in urology 18: 71-77.
7. Scheenen TW, Heijmink SW, Roell SA, Hulsbergen-Van de Kaa CA, Knipscheer BC, et al. (2007) Three-dimensional proton MR spectroscopy of human prostate at 3 T without endorectal coil: feasibility. Radiology 245: 507-516.
8. Swanson MG, Vigneron DB, Tabatabai ZL, Males RG, Schmitt L, et al. (2003) Proton HR-MAS spectroscopy and quantitative pathologic analysis of MRI/3D-MRSI-targeted postsurgical prostate tissues. Magnetic Resonance in Medicine 50: 944-954.
9. Swanson MG, Zektzer AS, Tabatabai ZL, Simko J, Jarso S, et al. (2006) Quantitative analysis of prostate metabolites using 1H HR-MAS spectroscopy. Magnetic Resonance in Medicine 55: 1257-1264.
10. Tessem MB, Swanson MG, Keshari KR, Albers MJ, Joun D, et al. (2008) Evaluation of lactate and alanine as metabolic biomarkers of prostate cancer using 1H HR-MAS spectroscopy of biopsy tissues. Magnetic Resonance in Medicine 60: 510-516.
11. Verma S, Rajesh A, Fütterer JJ, Turkbey B, Scheenen TWJ, et al. (2010) Prostate MRI and 3D MR Spectroscopy: How We Do It. American Journal of Roentgenology 194: 1414-1426.
12. Kobus T, Hambrock T, Hulsbergen-van de Kaa CA, Wright AJ, Barentsz JO, et al. (2011) In Vivo Assessment of Prostate Cancer Aggressiveness Using Magnetic Resonance Spectroscopic Imaging at 3 T with an Endorectal Coil. European Urology 60: 1074-1080.
13. Keshari KR, Tsachres H, Iman R, Delos Santos L, Tabatabai ZL, et al. (2011) Correlation of phospholipid metabolites with prostate cancer pathologic grade, proliferative status and surgical stage - impact of tissue environment. NMR in biomedicine 24: 691-699.
14. Cheng LL, Wu C-l, Smith MR, Gonzalez RG, (2001) Non-destructive quantitation of spermine in human prostate tissue samples using HRMAS 1H NMR spectroscopy at 9.4 T. FEBS Letters. 494: 112-116.
15. Bertilsson H, Tessem M-B, Flatberg A, Viset T, Gribbestad I, et al. (2012) Changes in Gene Transcription Underlying the Aberrant Citrate and Choline Metabolism in Human Prostate Cancer Samples. Clinical Cancer Research 18: 3261-3269.
16. Santos CF, Kurhanewicz J, Tabatabai ZL, Simko JP, Keshari KR, et al. (2010) Metabolic, pathologic, and genetic analysis of prostate tissues: quantitative evaluation of histopathologic and mRNA integrity after HR-MAS spectroscopy. NMR in biomedicine 23: 391-398.
17. Selnaes KM, Gribbestad IS, Bertilsson H, Wright A, Angelsen A, et al. (2012) Spatially matched in vivo and ex vivo MR metabolic profiles of prostate cancer- investigation of a correlation with Gleason score. NMR in biomedicine.
18. Bertilsson H, Angelsen A, Viset T, Skogseth H, Tessem M-B, et al. (2011) A new method to provide a fresh frozen prostate slice suitable for gene expression study and MR spectroscopy. The Prostate 71: 461-469.
19. Swanson MG, Vigneron DB, Tran TK, Sailasuta N, Hurd RE, et al. (2001) Single-voxel oversampled J-resolved spectroscopy of in vivo human prostate tissue. Magnetic resonance in medicine: official journal of the Society of Magnetic Resonance in Medicine/Society of Magnetic Resonance in Medicine 45: 973-980.
20. Savorani F, Tomasi G, Engelsen SB, (2010) icoshift: A versatile tool for the rapid alignment of 1D NMR spectra. Journal of Magnetic Resonance 202: 190-202.
21. Wold S, Sjöström M, Eriksson L, (2001) PLS-regression: a basic tool of chemometrics. Chemometrics and Intelligent Laboratory Systems 58: 109-130.
22. Westerhuis J, Hoefsloot H, Smit S, Vis D, Smilde A, et al. (2008) Assessment of PLSDA cross validation. Metabolomics 4: 81-89.
23. Chong I-G, Jun C-H, (2005) Performance of some variable selection methods when multicollinearity is present. Chemometrics and Intelligent Laboratory Systems 78: 103-112.
24. Provencher SW, (1993) Estimation of metabolite concentrations from localized in vivo proton NMR spectra. Magnetic Resonance in Medicine 30: 672-679.
25. Opstad KS, Wright AJ, Bell BA, Griffiths JR, Howe FA, (2010) Correlations between in vivo 1H MRS and ex vivo 1H HRMAS metabolite measurements in adult human gliomas. Journal of Magnetic Resonance Imaging 31: 289-297.
26. Swanson MG, Keshari KR, Tabatabai ZL, Simko JP, Shinohara K, et al. (2008) Quantification of choline- and ethanolamine-containing metabolites in human prostate tissues using 1H HR-MAS total correlation spectroscopy. Magnetic resonance in medicine: official journal of the Society of Magnetic Resonance in Medicine/Society of Magnetic Resonance in Medicine 60: 33-40.
27. Rantalainen M, Cloarec O, Beckonert O, Wilson ID, Jackson D, et al. (2006) Statistically Integrated Metabonomic-Proteomic Studies on a Human Prostate Cancer Xenograft Model in Mice. Journal of proteome research 5: 2642-2655.
28. Govindaraju V, Young K, Maudsley AA, (2000) Proton NMR chemical shifts and coupling constants for brain metabolites. NMR in biomedicine 13: 129-153.
29. Bates D, Maechler M, Bolker B (2011) lme4: Linear mixed-effects models using S4 classes. R package version 0.999375-42.
30. Shukla-Dave A, Hricak H, Moskowitz C, Ishill N, Akin O, et al. (2007) Detection of prostate cancer with MR spectroscopic imaging: an expanded paradigm incorporating polyamines. Radiology 245: 499-506.
31. van der Graaf M, Schipper RG, Oosterhof GO, Schalken JA, Verhofstad AA, et al. (2000) Proton MR spectroscopy of prostatic tissue focused on the detection of spermine, a possible biomarker of malignant behavior in prostate cancer. MAGMA 10: 153-159.
32. Klomp DWJ, Scheenen TWJ, Arteaga CS, van Asten J, Boer VO, et al. (2011) Detection of fully refocused polyamine spins in prostate cancer at 7 T. NMR in biomedicine. 24: 299-306.
33. van Asten JJ, Cuijpers V, Hulsbergen-van de Kaa C, Soede-Huijbregts C, Witjes JA, et al. (2008) High resolution magic angle spinning NMR spectroscopy for metabolic assessment of cancer presence and Gleason score in human prostate needle biopsies. MAGMA 21: 435-442.
34. Moestue SA, Giskeødegård GF, Cao MD, Bathen TF, Gribbestad IS, (2012) Glycerophosphocholine (GPC) is a poorly understood biomarker in breast cancer. Proceedings of the National Academy of Sciences of the United States of America 109: E2506.
35. Zakian KL, Sircar K, Hricak H, Chen H-N, Shukla-Dave A, et al. (2005) Correlation of Proton MR Spectroscopic Imaging with Gleason Score Based on Step-Section Pathologic Analysis after Radical Prostatectomy1. Radiology 234: 804-814.
36. Bertilsson H (2012) Prostate Cancer- Translational Research. Optimizing tissue sampling suitable for histopathologic, transcriptomic and metabolic profiling [PhD thesis]. Trondheim: Norwegian University of Science and Technology. ISBN 978-82-471-3786-4 (electronic ver.).
37. Wilson M, Davies NP, Grundy RG, Peet AC, (2009) A quantitative comparison of metabolite signals as detected by in vivo MRS with ex vivo 1H HR-MAS for childhood brain tumours. NMR in biomedicine 22: 213-219.
38. Tkac I, Rao R, Georgieff MK, Gruetter R, (2003) Developmental and regional changes in the neurochemical profile of the rat brain determined by in vivo 1H NMR spectroscopy. Magnetic Resonance in Medicine 50: 24-32.